Today's Clinical Results Seem Promising Today's clinical update seems promising compared to other trials done in advanced pancreatic cancer.
In a study using acalabrutinib alone or with pembrolizumab, the overall response rate and disease control rate were 0% and 14.3% with monotherapy and 7.9% and 21.1% with combination therapy, respectively. [1]
Another study, using Durvalumab with or without Tremelimumab, reported an overall response rate of 3.1% for patients treated with combination therapy and 0% for patients treated with monotherapy. The disease control rate at 3 months was 9.4% for patients treated with combination therapy and 6.1% for patients treated with monotherapy. [2]
Oncolytics reports that their study achieved a disease control rate of 42%. I look forward to reading the full poster presentation when it's released in June.
[1]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057435 - Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
[2]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647002 - Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma